Key Highlights:
- Sangamo Therapeutics (SGMO, Financial) secures an exclusive licensing agreement with Eli Lilly.
- Potential deal value reaches up to $1.4 billion, starting with an $18 million upfront payment.
- Analyst consensus highlights significant upside potential with a price target average of $5.00.
Sangamo Therapeutics (SGMO) has recently inked an exclusive licensing agreement with the pharmaceutical giant Eli Lilly. This strategic alliance centers around Sangamo's cutting-edge STAC-BBB capsid technology, aimed at advancing neurological therapies. The agreement provides Sangamo with an immediate financial boost of $18 million, with the prospective milestones and royalty payments capable of reaching a staggering $1.4 billion.
Analyst Expectations and Price Projection
According to an analysis by six industry experts, the average one-year price target for Sangamo Therapeutics Inc (SGMO, Financial) stands at $5.00. The analysts present a high-end estimate of $10.00 and a low of $2.00, offering an expansive outlook on the company's potential growth. Remarkably, this average target signals a remarkable upside of 703.47% from the current trading price of $0.62. For a more comprehensive insight into these projections, investors are encouraged to visit the Sangamo Therapeutics Inc (SGMO) Forecast page.
Brokerage Recommendations and GF Value Estimation
The consensus from eight brokerage firms indicates an "Outperform" status for Sangamo Therapeutics Inc (SGMO, Financial), with an average recommendation of 2.3 on a scale where 1 signifies Strong Buy and 5 represents Sell. This consensus underscores a positive outlook from industry professionals.
Delving into GuruFocus's proprietary metrics, the estimated GF Value for Sangamo Therapeutics Inc (SGMO, Financial) within the next year is projected at $1.17. This estimation denotes an upside of 88.01% from the current price level of $0.6223. The GF Value is meticulously computed based on historical trading multiples, past growth trajectories, and anticipated future business performance. Detailed insights are available on the Sangamo Therapeutics Inc (SGMO) Summary page.
